In the present study, we found that the combination treatment of Cabozantinib and IL-32γ overexpression further increased the number of LC3 puncta and colocalization with LC3 and LAMP1 in liver cancer cell lines. This evidence concerns the gene MAP1LC3A and liver cancer.